P53、MDM2蛋白在肾细胞癌的表达及意义  

Expression of MDM2 and P53 in renal cell carcinoma

作　　者：邹泓[1] 李锋[1] 庞丽娟[1] 胡文浩[1] 刘春霞[1] 李洪安[1] 蒋金芳[1] 梁伟华[1] 郭长军[1] 王嘉志[1] 

机构地区：[1]石河子大学医学院病理教研室,新疆石河子832002

出　　处：《中国现代医学杂志》2009年第15期2241-2244,共4页China Journal of Modern Medicine

基　　金：国家自然科学基金(30560169);石河子大学高层次人才科研启动基金(RCZX200784)

摘　　要：目的通过检测P53和MDM2蛋白在肾细胞癌中的表达,探讨它们与肾癌的发生与临床分期的关系。方法免疫组织化学方法检测114例肾癌中MDM2、P53蛋白的表达,并分组进行统计。结果MDM2蛋白在肾透明细胞癌中阳性率为54.5%(42/77),与其它亚型表达有显著差异;P53蛋白在肾未化癌、Xp11.2/TFE3基因融合相关性肾癌的阳性率分别为100.0%(2/2)和70.0%(7/10);P53蛋白的表达率随肾癌TNM分期增高呈上升趋势,在TNMI、II期与TNM III、IV期组间表达差异有显著性(χ2=9.4119,P=0.0022);MDM2与P53共同表达的肾透明细胞癌比例随TNM分级升高而升高,在TNMI、II期与TNM III、IV期组间表达差异有显著性(χ2=6.2938,P=0.0121)。结论MDM2可能参与肾透明细胞癌的发生,P53可能参与Xp11.2/TFE3基因融合相关性肾癌、未分化癌的发生发展。P53阳性可能是肾癌的不利预后指标,MDM2与P53蛋白在肾透明细胞癌中的联合表达提示预后不佳。[Objective] To investigate the expression of MDM2 and P53 in renal cell carcinoma （RCC）. [Methods] Protein expression of MDM2 and P53 in 114 RCC tissues was examined by immunohistochemical assay. [Resuits] Immunohistochemical study showed that the expression rates of MDM2 in clear cell renal cell carcinoma （CCRCC） were 54.5% （42/77）. On the other hand, the expression rates of P53 in undifferentiated renal ceil carcinoma （unRCC） and Xpl 1.2 translocations / TFE3 gene fusions （Xp11.2RCC） were 100% （2/2）, 70% （7/10）, the differences of expression rate between different TNM I, Ⅱ stage and TNM III, VI stage have statistical significance （χ^2= 9.4119, P=0.0022）. the coexpression rate of P53 and MDM2 protein were increased with the TNM stage, and the differences of coexpression rate between different TNM I, II stage and TNM III, VI stage have statistical significance （χ^2=6.2938, P =0.0121）. [Conclusions] MDM2 may play role in developing of CCRCC, P53 gene may play role in progression of Xp11.2RCC and unRCC. The expression of P53 may be related to poor prognosis of RCC, the coexpression of MDM2 and P53 may indicate poor survival for CCRCC.

关 键 词：肾肿瘤 癌 P53 MDM2 

分 类 号：R737.11[医药卫生—肿瘤]